FDA approved a new indication for semaglutide (Wegovy) to reduce the risk of cardiovascular death, myocardial infarction, and stroke in adults with CVD and either obesity or overweight (Lincoff et al., 2023)
Patients often report improved recovery times, decreased soreness, and better exercise tolerance
A person who weighs the same at month 10 as they did at month 8 but has gained 3 pounds of muscle and lost 3 pounds of fat looks dramatically different
Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
This increased dream recall indicates you are spending more time in REM sleep phases, which typically follow deep slow-wave sleep cycles